German Pharma Enters the Clinic with Solid Tumor Treatment

A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors.

Immatics is a German biopharma based in Tuebingen, which is a leader in the field of cancer immunotherapy. It has announced today the initiation of a Phase I trial that will test the safety and tolerability of its candidate, ACTengine. The therapy is targeted at non-small cell lung cancer or head and neck squamous cell carcinoma, which currently lack a standard of care.

The ACTengine approach is made up of several exciting features. Immatic’s XPRESIDENT high-throughput target discovery platform identifies a tumor antigen to target. A biomarker profile is used to make sure the antigen is present on the patient’s tumor, and if so, the patient’s T cells are engineered to express a T cell receptor (TCR) against the antigen. The T cells are multiplied, activated and infused back into the body where they recognize their target with very high affinity and clear out the tumor.

Immatics joins a busy field, with a number of groups, including Adaptimmune and Immunocore that are investigating TCR-based therapies in particular. The company will hope that the combination of both target-identification and treatment technologies will give it an advantage over others.


Image – CI Photos / shutterstock.com

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.